The Problem With Current Proposals to Address High Medicare Part B Drug Prices Gregory W. Daniel Editorial 19 December 2019 Pages: 721 - 723
Awareness and Collaboration Across Stakeholder Groups Important for eConsent Achieving Value-Driven Adoption Hilde VanakenShirley N. Masand TransCelerate Special Section: Original Article Open access 19 December 2019 Pages: 724 - 735
Industry Assessment of the Contribution of Patient Support Programs, Market Research Programs, and Social Media to Patient Safety Jeremy JokinenDominique BertinPeter Verdru TransCelerate Special Section: Original Article Open access 19 December 2019 Pages: 736 - 745
Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D Duane SchulthessDaniel GassullSteven Maisel Value & Access: Commentary 19 December 2019 Pages: 746 - 751
Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016 G. Caleb AlexanderKen OgasawaraChristopher D. Breder Regulatory Science: Original Article 19 December 2019 Pages: 752 - 758
Potential Use of Artificial Intelligence for Regulatory Intelligence: Biopharmaceutical Industry’s Views Mark MayerAngelica CanedoChloé Garay Regulatory Science: Original Article 19 December 2019 Pages: 759 - 766
The Meanings of “Pediatric Drug Development” Klaus RoseJane M. Grant-Kels Special Populations: Review Article 19 December 2019 Pages: 767 - 774
Recalls and Premarket Review Systems for High-Risk Medical Devices in Japan Motoko NakayamaShiro TanakaKoji Kawakami Global Perspectives: Original Article 19 December 2019 Pages: 775 - 780
Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and Perspectives Jobin JoseNaziya Refi Rafeek Global Perspectives: Review Article 19 December 2019 Pages: 781 - 786
Scope of Improvement in the Functioning of National Regulatory Authority—A Step Toward International Accreditation: A Qualitative Study From Pakistan Raazeyah IkramAnum SaqibMuhammad Atif Global Perspectives: Original Article 19 December 2019 Pages: 787 - 794
Detecting Adverse Drug Events: Accuracy and Generalizability Scott R. WalterBlanca Gallego Regulatory Science: Commentary 19 December 2019 Pages: 795 - 796
Erratum to “Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development” Elizabeth YenJonathan M. DavisChristopher-Paul Milne Erratum 19 December 2019 Pages: 797 - 797